![]() ![]() Stopping was no more frequent for statin than placebo (P = 0.173), and subsequent symptom relief was similar between statin and placebo. ![]() ![]() In the individual-patient daily data, neither symptom intensity on starting (OR: 1.02 95% CI: 0.98-1.06 P = 0.28) nor extent of symptom relief on stopping (OR: 1.01 95% CI: 0.98-1.05 P = 0.48) distinguished between statin and placebo. Mean symptom score was 8.0 (95% CI: 4.7-11.3) in no-tablet months. We also measured the "nocebo" ratio: the ratio of symptoms induced by taking statin that was also induced by taking placebo.Ī total of 60 participants were randomized and 49 completed the 12-month protocol. We measured daily symptom intensity for each using an app (scale 1-100). ![]() Participants received 12 1-month medication bottles, 4 containing atorvastatin 20 mg, 4 placebo, and 4 empty. The purpose of this study was to assess daily symptom scores on statin, placebo, and no treatment in participants who had abandoned statins. Most people who begin statins abandon them, most commonly because of side effects. ![]()
0 Comments
Leave a Reply. |